financetom
Business
financetom
/
Business
/
Jfrog Insider Sold Shares Worth $1,144,500, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Jfrog Insider Sold Shares Worth $1,144,500, According to a Recent SEC Filing
May 22, 2024 3:06 PM

05:32 PM EDT, 05/22/2024 (MT Newswires) -- Frederic Simon, Director, on May 21, 2024, sold 35,000 shares in Jfrog ( FROG ) for $1,144,500. Following the Form 4 filing with the SEC, Simon has control over a total of 4,619,432 shares of the company, with 4,619,432 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1800667/000141588924014125/xslF345X03/form4-05222024_090508.xml

Price: 33.80, Change: +0.34, Percent Change: +1.02

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Viatris' Q3 Earnings, Revenue Decline; 2024 Adjusted EPS Guidance Lowered
Viatris' Q3 Earnings, Revenue Decline; 2024 Adjusted EPS Guidance Lowered
Nov 9, 2024
08:14 AM EST, 11/07/2024 (MT Newswires) -- Viatris ( VTRS ) reported Q3 adjusted earnings Thursday of $0.75 per diluted share, compared with $0.79 a year earlier. Analysts surveyed by Capital IQ expected $0.68. Revenue for the quarter ended Sept. 30 was $3.74 billion, compared with $3.93 billion a year earlier. Analysts surveyed by Capital IQ expected $3.71 billion. For...
Carlyle Group's Q3 Distributable Earnings, Revenue Rise
Carlyle Group's Q3 Distributable Earnings, Revenue Rise
Nov 9, 2024
08:10 AM EST, 11/07/2024 (MT Newswires) -- Carlyle Group ( CG ) reported Q3 after-tax distributable earnings Thursday of $0.95 per diluted share, up from $0.87 a year earlier. Analysts polled by Capital IQ expected $0.89. Total segment revenue for the quarter ended Sept.30 was $895 million, up from $776.6 million a year earlier. Analysts surveyed by Capital IQ expected...
HLS Therapeutics Q3 Loss Narrows
HLS Therapeutics Q3 Loss Narrows
Nov 9, 2024
08:12 AM EST, 11/07/2024 (MT Newswires) -- HLS Therapeutics ( HLTRF ) on Thursday reported a narrower third-quarter loss. The net loss fell to US$4.84 million, or US$0.15 per share, from US$6.9 million, or US$0.21 per share, last year. Revenue fell to US$14.1 million from US$16 million. HLS cut its revenue range to US$56.5-57.2 million from the previous US$58.5-59.7 million....
US FDA approves Johnson & Johnson's device for heart condition
US FDA approves Johnson & Johnson's device for heart condition
Nov 9, 2024
Nov 7 (Reuters) - The U.S. Food & Drug Administration has approved Johnson & Johnson's ( JNJ ) device for a type of heart condition, the company said on Thursday. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved